Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study.
Daijo InagumaFumihiko KoiwaMasanori TokumotoMasafumi FukagawaShinji YonedaHisami YasuzawaKenji AsanoKeiko HagitaYosuke InagakiDaisuke HondaTadao AkizawaPublished in: Clinical kidney journal (2023)
In haemodialysis patients with SHPT, upacicalcet doses of 25-300 μg for 52 weeks were found to be highly effective and well-tolerated, with minor safety concerns.